Basic Information
| LncRNA/CircRNA Name | Llme23 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | melanoma |
| ICD-0-3 | NA |
| Methods | qPCR, RNAi, Western blot, Northern blot, RIP etc. |
| Sample | cell lines (MCF10A, HEK293, A2058, SKmel28, YU-SIT1, YUSAC etc.) |
| Expression Pattern | differential expression |
| Function Description | The specific binding of Llme23 to both recombinant and native PSF protein was confirmed in vitro and in vivo. The expression of PSF-binding Llme23 is exclusively detected in human melanoma lines. Knocking down Llme23 remarkably suppressed the malignant property of YUSAC cells, accompanied by the repressed expression of proto-oncogene Rab23. These results may indicate that Llme23 can function as an oncogenic RNA and directly associate the PSF-binding lncRNA with human melanoma. |
| Pubmed ID | 23618401 |
| Year | 2013 |
| Title | The non-coding RNA llme23 drives the malignant property of human melanoma cells. |
External Links
| Links for Llme23 | GenBank HGNC NONCODE |
| Links for melanoma | OMIM COSMIC |